Infliximab May Impede Serologic Response to SARS-CoV-2
Concomitant immunomodulator use further blunted antibody responses to SARS-CoV-2 among infliximab-treated IBD patients
Colorectal Disorders
Clinical Remission Reported With Mirikizumab in Ulcerative Colitis Trial
LUCENT-1 is a 12-week, double-blind, placebo-controlled induction study evaluating mirikizumab in over 1100 UC patients who had an inadequate response to, loss of response, or were intolerant to conventional or biologic therapy for UC.
Increased Risk of Eosinophilic Esophagitis in Children With IBD
Researchers evaluated the potential predictive characteristics of eosinophilic esophagitis following IBD diagnosis in children.
Amoxicillin-Clavulanate Effective for Outpatients With Diverticulitis
As effective as metronidazole with fluoroquinolone, with reduced risk for one-year Clostridioides difficile infection
Upadacitinib Meets End Points in Ulcerative Colitis Trial
The U-ACCOMPLISH induction study evaluated the efficacy and safety of upadacitinib in 515 adults with moderate to severe ulcerative colitis.
Ozanimod Gets Priority Review for Ulcerative Colitis
The submission is supported by data from the True North trial that assessed ozanimod as an induction and maintenance therapy for adults with moderately to severely active UC who had an inadequate response to prior treatment.
De-Escalation and Discontinuation of Biologics in IBD: What to Consider
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
Clinical Remission Observed With Risankizumab in Crohn Disease Trials
Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.
Generic Version of Amitiza Now Available
The Company has begun shipping both the 8mcg and 24mcg capsules; the capsules are supplied in 60-count bottles.
FDA to Review AVT02, a High Concentration Biosimilar to Adalimumab
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
